Macrophages, predominant cells in dialysates of patients on CAPD without peritonitis, produce a wide variety of substances including cytokines. The aim of this study was to examine the cytokine production in five uninfected patients. This work investigated the presence in dialysates of interleukin-1ß, interleukin-6, interleukin-8, tumor necrosis factor α and the ability of peritoneal macrophages to produce these cytokines. These results were compared with values obtained from control group in non-uremic conditions (peritoneal lavage with isotonic saline or dialysis fluid). All cytokines were detectable in dialysates. Interindividual variations in cytokine concentration in dialysates were wider than variations of production of cytokines ex vivo by stimulated and unstimulated cells. In control group, dialysis fluid inhibited the cytokine production and with isotonic saline, cells produced less cytokines than dialysis patients'cells. The highest levels of interleukin-1 and tumor necrosis factor in dialysates and the highest capacity to respond to LPS were observed in patients having the shortest duration of dialysis. The variability observed did not seem to be due to cells themselves but to their environment.
NathanC.F.. Secretory products of macrophages.J Clin Invest1987; 79: 319–26.
7.
CavaillonJ.M.. Cytokines and macrophages.Biomed Pharmacother1994; 48: 445–53.
8.
Haeffner-CavaillonN., KazatchkineM.D.. Methods for assessing monocytic cytokine production as an index of biocompatibility.Nephrol Dial Transplant1994; 9(suppl 2): S112–5.
9.
MartyC., MissetB., TamionS., FittingC., CarletJ., CavaillonJ.M.. Circulating interleukin-8 concentrations in patients with multiple organ failure of septic or non septic origins.Crit Care Med1994; 22: 673–9.
10.
NakanishiI., MoutabarrakA., OkadaN.. Interleukin-8 in chronic renal failure and dialysis patients.Nephrol Dial Transplant1994; 9: 1435–42.
11.
MouabarrakA., NakanishiI., NamikiM., TsubakiharaY.. Interleukin-1 and its naturally occurring antagonist in peritoneal dialysis patients.Clin Nephrol1995; 43: 243–8.
12.
ZemelD., KredietR.T., KoomenG.C.M., KortekassW.M.R., GeertzenH.G.M., Ten BergeR.J.M.. Interleukin-8 during peritonitis in patients treated with CAPD; an in-vivo model of acute inflammation.Nephrol Dial Transplant1994; 9: 169–74.
13.
LewisS.L., NorrisP.J.. Monocyte/macrophage function in CAPD patients.Contrib Nephrol1990; 85: 1–9.
14.
FriedlanderM.A., HilbertC.M., YU ChingW.U., RichE.A.. Role of dialysis modality in responses of blood monocytes and peritoneal macrophages to endotoxin stimulation.Am J Kidney Dis1993; 22: 11–23.
15.
TopleyN., WilliamsJ.D.. Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity.Kidney Int1994; 46(suppl 48): S71–8.
16.
ZemelD., Ten BergeR.J.M., StruijkD.G., BloemenaE., KoomenG.C.M., KredietR.T.. Interleukin-6 in CAPD patients without peritonitis: relationship to the intrinsic permeability of the peritoneal membrane.Clin Nephrol1992; 37: 97–103.
17.
GoldmanM., VandenabeeleP., MoulartJIntraperitoneal secretion of interleukin-6 during continuous ambulatory peritoneal dialysis.Nephron1990; 56: 277–80.
18.
MarianoF., TettaC., MontrucchioG., CavalliP.L., CamussiG.. Role of α1-proteinase inhibitor in restraining peritoneal inflammation in CAPD patients.Kidney Int1992; 42: 735–42.
19.
BraunerA., HylanderB., WretlindB.. Interleukin-6 and interleukin-8 in dialysate and serum from patients on continuous ambulatory peritoneal dialysis.Am J Kidney Dis1993; 22: 430–5.
20.
LinC.H., HuangT.P.. Gene expression and release of interleukin-8 by peritoneal macrophages and polymorphonuclear leukocytes during peritonitis in uremic patients on continuous ambulatory peritoneal dialysis.Nephron1994; 68: 437–41.
21.
BosH.J., MeyerF., De VeldJ.C., BeelenR.H.J.. Peritoneal dialysis fluids induces change of mononuclear phagocyte proportions.Kidney Int1989; 36: 20–6.
22.
FuhlbriggeR.C., ChaplinD.D., KielyJ.M., UnanueE.R.. Regulation of interleukin 1 gene expression by adherence and lipopolysaccharide.J Immunol1987; 138: 3799–802.
23.
TopleyN., KaurD., PetersenM.M.. Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function.Kidney Int1996; 49: 1447–56.
24.
Mc KennaR.M., MacdonaldC., BernsteinK.N., RushD.N.. Increased production of tumor necrosis factor activity by hemodialysis but not peritoneal dialysis patients.Nephron1994; 67: 190–6.
25.
LynchE.A., DinarelloC.A., CannonJ.G.. Gender differences in IL-1α, IL-1ß, IL-1 receptor antagonist secretion from mononuclear cells and urinary excretion.J Immunol1994; 153: 300–6.
26.
MolvigJ., BackL., ChristensenP.. Endotoxin-stimulated human monocyte secretion of interleukin 1, tumor necrosis factor alpha, and prostaglandin E2 shows stable interindividual differences.Scan J Immunol1988; 27: 705–15.
27.
JorresA., TopleyN., SteenwegL., MullerC., KottgenE., GahlG.M.. Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle.Am J Nephrol1992; 12: 80–5.
28.
LinC.H., KuW.L., HuangT.P.. Serial peritoneal macrophage function studies in new and established continuous ambulatory peritoneal dialysis patients.Am J Nephrol1990; 10: 368–73.
29.
SothernR.B., Roitman-JohnsonB., KanabrockiE.L.. Circadian characteristics of circulating interleukin-6 in men.J Allergy Clin Immunol1995; 95: 1029–35.
30.
PereiraB.J.G., DinarelloC.A.. Production of cytokines and cytokine inhibitory proteins in patients on dialysis.Nephrol Dial Transplant1994; 9(suppl 2): 60–71.
31.
MunozC., SchlessingerL., CavaillonJ.M.. Interaction between cytokines, nutrition and infection, (in press, Nutrition Research).
